Disclaimer: Statements have not been evaluated by the FDA or any other regulatory authority
Disclosure of interest: Han-Yeong Jeong: nothing to disclose, Seong-Eun Kim: nothing to disclose, Eung-Joon Lee: nothing to disclose, Jayoun Kim: nothing to disclose, Nan Hee Park: nothing to disclose, Joongyub Lee: nothing to disclose, Ji Sung Lee: nothing to disclose, Juneyoung Lee: nothing to disclose, Jinju Park: nothing to disclose, Jin-Hyuk Hong: nothing to disclose, Hyun-Jae Kang: nothing to disclose, Keun-Hwa Jung: nothing to disclose, Hee-Joon Bae: nothing to disclose E-Posters - QUALITY OF LIFE 08.00 - QUALITY OF LIFE - 08.01 - CLINICAL PRACTICE, MANAGEMENT AND CARE P2614 - ESOC25-1795 MOOD DISTURBANCES AND COGNITIVE ASSESSMENT IN CADASIL PATIENTS Carolina De Toma 1 , Nicola Rifino 1 , Esteban Zacarias 1 , Giulia Marinoni 1 , Camilla Strazzabosco 1 , Benedetta Storti 1 , Giorgio Boncoraglio 1 , Isabella Canavero 1 , Anna Bersano 1 1 Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy Background and Aims: CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) leads to recurrent strokes and cognitive dysfunctions but it could also lead to depression and mood disturbances
They suggest that increasing glutathione levels may improve psoriasis symptoms
A professional evaluation helps determine whether glutathione injections in Antalya are appropriate based on the patients medical history, current health status, and treatment goals
